Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Recruiting · NCT03810339 · Registry updated 2026-04-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors | Advanced Cancer; Solid Tumor | Recruiting | Phase 2 | 2026-04-23 | NCT03810339 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sun Yat-sen University | 606 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer center of Sun Yat-sen University | Guangzhou | China | 5 |
| the Affiliated Hospital of Guizhou Medical University | Guiyang | China | 29 |
| The Second Affiliated Hospital of Dalian Medical University | Dalian | China | 4 |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | China | 20 |